Market Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry

MT Newswires Live

2025/10/09

Novo Nordisk (NVO) Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.

"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do," Doustdar said, according to the report.

The company can't "shy away in taking some additional risks," the CEO said, according to the report.

On Thursday, Novo agreed to buy Akero Therapeutics (AKRO) for up to $5.2 billion in cash.

Novo didn't immediately reply to a request for comment from MT Newswires.

Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 58.82, Change: -0.79, Percent Change: -1.33

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2574164139"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574164139\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574164139?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-09 23:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574164139","market":"us","top_or_hot":-1,"title":"Market Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.</p><p>\"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do,\" Doustdar said, according to the report.</p><p>The company can't \"shy away in taking some additional risks,\" the CEO said, according to the report.</p><p>On Thursday, Novo agreed to buy <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> (AKRO) for up to $5.2 billion in cash.</p><p>Novo didn't immediately reply to a request for comment from MT Newswires.</p><p>Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 58.82, Change: -0.79, Percent Change: -1.33</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-09 23:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.</p><p>\"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do,\" Doustdar said, according to the report.</p><p>The company can't \"shy away in taking some additional risks,\" the CEO said, according to the report.</p><p>On Thursday, Novo agreed to buy <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> (AKRO) for up to $5.2 billion in cash.</p><p>Novo didn't immediately reply to a request for comment from MT Newswires.</p><p>Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 58.82, Change: -0.79, Percent Change: -1.33</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2574164139","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574164139","pubTimestamp":1760025337,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.\"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do,\" Doustdar said, according to the report.The company can't \"shy away in taking some additional risks,\" the CEO said, according to the report.On Thursday, Novo agreed to buy Akero Therapeutics  for up to $5.2 billion in cash.Novo didn't immediately reply to a request for comment from MT Newswires.Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.Price: 58.82, Change: -0.79, Percent Change: -1.33","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","NVO.AU":"NOVO RESOURCES CORP-CDI","BK4139":"生物科技","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","AKRO":"Akero Therapeutics","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK7104":"黄金","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","NVO":"诺和诺德"},"translate_title":"市场热议：诺和诺德首席执行官准备在减肥竞争中冒险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":1,"NVO.AU":1,"NVO":1.5},"content_text":"Novo Nordisk (NVO) Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.\"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do,\" Doustdar said, according to the report.The company can't \"shy away in taking some additional risks,\" the CEO said, according to the report.On Thursday, Novo agreed to buy Akero Therapeutics (AKRO) for up to $5.2 billion in cash.Novo didn't immediately reply to a request for comment from MT Newswires.Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: 58.82, Change: -0.79, Percent Change: -1.33","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}